This trial is evaluating whether WST-057 will improve 4 primary outcomes and 8 secondary outcomes in patients with Polyneuropathies. Measurement will happen over the course of 16 weeks.
This trial requires 60 total participants across 2 different treatment groups
This trial involves 2 different treatments. WST-057 is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
"Peripheral neuropathies are often treated with medications, such as anticonvulsants, bisphosphonates, and antiepileptics, or with physical therapy. When medication proves ineffective, tranexamic acid can be a valuable alternative. In the case that an antitoxin for botulinum toxin therapy is unavailable, a trial of botulinum toxin A (Botox) is effective. Botulinum toxin A is usually injected by muscle biopsy. When Botox is not an option, surgery often is needed to excise the nerve. Nerve blocks are also one of several options. If a surgery is required, peripheral nerve blockade is sometimes used." - Anonymous Online Contributor
"About 3.8 million Americans have at least one polyneuropathy. Most polyneuropathies can be explained with either peripheral neuropathy, Guillain-Barré syndrome, tabes dorsalis, or a combination of them." - Anonymous Online Contributor
"Polyneuropathy can be caused by traumatic injuries and/or medical conditions such as diabetes mellitus, alcoholism, and certain types of cancer. It can also be a symptom of illnesses such as SLE, AIDS, and infectious diseases. To find active epilepsy clinical trials in your area, you can use Power. The condition often affects adults in their late 30s and 40s, but the onset is often delayed. People with polyneuropathy are often hesitant about seeking help because they do not know where to start. To find active polyneuropathy clinical trials in your area, use [Power](http://www.withpower." - Anonymous Online Contributor
"The evidence that axonal polyneuropathy is not easily cured led to reconsideration of the definition of 'cure' of polyneuropathy. This has led to the conclusion that all forms of polyneuropathy can be cured in some patients but that recovery of sensory and autonomic function from polyneuropathy is dependent on the type of polyneuropathy and the nature of the treatment. Such findings warrant consideration of the value of new treatments." - Anonymous Online Contributor
"The clinical suspicion of polyneuropathy can be determined by the signs and symptoms, and can be more accurately interpreted with testing. The most helpful parameter for the diagnosis of sensory polyneuropathies is needle electromyography which can help to distinguish between critical polyneuropathy and polyneuropathy. In severe sensory polyneuropathies the diagnosis may be confirmed by electrodiagnostic studies." - Anonymous Online Contributor
"For the most part, the most frequent clinical features were sensory and motor disturbances, autonomic disturbances and gastrointestinal disturbances, often presenting with some degree of neuropathy, with or without neurologic signs. However, polyneuropathies can vary in the distribution and clinical manifestations, depending on the type of polyneuropathy and the severity of the disease." - Anonymous Online Contributor
"Wst-057 significantly improved the quality of life of people with peripheral neuropathy. Data from a recent study provide the first evidence demonstrating that a pharmacological agent can contribute to improved quality of life. This is relevant given the growing interest in using novel therapeutics to delay the progression of disabling conditions." - Anonymous Online Contributor
"The presence or absence of polyneuropathy should not influence the decision to participate in a study of potential therapeutic benefit to patients with multiple sclerosis." - Anonymous Online Contributor
"These study results suggested that there was not a clinically important benefit for using a dual agent regimen containing Wst-057 and other drugs, with the possible exception of the use of such agents in patients with polyneuropathy." - Anonymous Online Contributor
"wst-057 has therapeutic benefit in a number of preclinical models, including models of amyotrophic lateral sclerosis, stroke, and stroke recovery. The preclinical data support further clinical investigation of wst-057 in multiple sclerosis and ALS." - Anonymous Online Contributor
"The average disease age is 57 years. Results from a recent clinical trial could not be powered for exact quantifications, but it does show a trend of earlier onset in patients with diabetes. Furthermore, the rate of progression decreases with age. There does not appear to be an association between polyneuropathy and smoking, alcoholism, diabetes, or duration of disease. More studies are needed to determine whether polyneuropathy does worsen with age and whether this relationship is due to polyneuropathy or to the development of diabetes." - Anonymous Online Contributor